FCPM III Services B.V. disclosed a new $65.6 million stake in Damora Therapeutics. The investment fund acquired 2,441,000 shares as of March 31, 2026. This position represents nearly 9% of the fund's reportable assets.
Damora, formerly known as Galecto, recently pivoted to focus on rare blood cancer therapies. The company's stock price surged approximately 700% over the past year. This investment precedes a mid-2026 regulatory submission for its lead candidate, DMR-001.
The company reported $532.9 million in cash at the end of the first quarter. Damora expects its current capital to fund operations into 2029.